Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study

Ionis Pharmaceuticals Inc IONS has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE).

  • The study met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by HAE patients compared to placebo.
  • Data demonstrated a mean reduction of 90% in the number of monthly HAE attacks in weeks one to 17 of the study and a mean decrease of 97% in the number of monthly HAE attacks in weeks five to 17
  • In weeks five to 17, 92% of patients treated with IONIS-PKK-LRx were attack-free compared to 0% in the placebo group.
  • On the safety front, most adverse events were mild with a frequency that was similar between groups.
  • The most common treatment-emergent adverse events were headaches and nausea, which were seen more frequently in the placebo arm than the active treatment arm.
  • The company will present a complete analysis of its Phase 2 study of IONIS-PKK-LRx at a medical conference later this year.
  • Price Action: IONS shares are trading 5.6% higher at $45.37 in market trading hours on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralhereditary angioedemaPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!